AccessibilityHelpAbout Us
Viva Biotech logo

Viva Biotech(OTC) VBIZF

Market Cap$395.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-66%
5 Year-76%
1 Year-41%
1 Month+19%
$0.19
+0.00%
+0.00Today
Viva Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.192026-08-24
Viva Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.23%USD 0.172026-08-04
1 month+18.7%USD 0.162026-07-01
3 month-5.43%USD 0.202026-05-21
Year to date-1.13%USD 0.192025-12-29
1 year-40.91%USD 0.322025-08-19
3 year-17.34%USD 0.232023-08-18
5 year-75.58%USD 0.792021-08-20
Since inception-66.07%USD 0.572019-09-25

Viva Biotech Financials at a Glance

Market Cap

$395.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥3.73B

Net Income (TTM)

CN¥348.70M

EPS (TTM)

$0.01

P/E Ratio

15.84

Dividend

$0.00

Beta (Volatility)

-0.13 (Low)

Price

$0.19

Volume

600

Open

$0.19

Previous Close

$0.19

Daily Range

$0.19 - $0.19

52-Week Range

$0.13 - $0.43

Estimated Earnings Date

Apr 1, 2027

VBIZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Viva Biotech

Viva Biotech Holdings is an investment holding enterprise specializing in comprehensive drug discovery services for biotechnology and pharmaceutical clients globally. The company employs a structure-based approach to facilitate the identification and development of promising drug candidates.

Products and Services
  • Discovery biology services, including protein expression and purification
  • Advanced chemistry services, such as medicinal and synthetic chemistry
  • Contract development and manufacturing (CDMO) for small molecule active pharmaceutical ingredients
Growth Outlook
  • Revenue of CNY 1.01 billion in Q2 2026, reflecting strong demand
  • Net income of CNY 80.08 million in Q2 2026, indicating profitability
  • Operating income margin of 11.1% in Q2 2026, showcasing operational efficiency
Financial Highlights
  • Trailing twelve months (TTM) P/E ratio of 11.48, suggesting attractive valuation
  • Gross profit margin of 37.9% TTM, indicating solid profitability
  • Cash and cash equivalents of CNY 1.00 billion as of Q2 2026, ensuring liquidity
Viva Biotech Holdings has established itself as a key player in the biotechnology sector, leveraging advanced technology platforms to deliver innovative solutions. The company's recent financial performance demonstrates robust growth and operational efficiency, making it an intriguing option for potential investors. With a strong focus on drug discovery and development, Viva Biotech is well-positioned to capitalize on the increasing demand for biopharmaceuticals. The solid cash position further enhances its ability to invest in future growth opportunities.
AI Generated • Aug 31, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

2,169

CEO

Chen Mao

Website

www.vivabiotech.com

Headquarters

Shanghai, SH 201318, CN

VBIZF Financials

Key Financial Metrics (TTM)

Gross Margin

34.55%

Operating Margin

10.05%

Net Income Margin

9.36%

Return on Equity

4.45%

Return on Capital

3.53%

Return on Assets

2.57%

Earnings Yield

6.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$395.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.07B

Volume

600

Avg. Volume

1.08K

Financials (TTM)

Gross Profit

CN¥1.34B

Operating Income

CN¥411.46M

EBITDA

CN¥816.30M

Operating Cash Flow

CN¥789.72M

Capital Expenditure

-CN¥284.42M

Free Cash Flow

CN¥505.30M

Cash & ST Invst.

CN¥1.03B

Total Debt

CN¥898.12M

Viva Biotech Performance Analysis

Viva Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 353,390,5688.3%
20232023-12-31CNY 304,244,079-13.9%
20242024-12-31CNY 276,045,763-9.3%
20252025-12-31CNY 240,586,839-12.8%
Viva Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-312.3%
Q22025-06-30-17.2%
Q42025-12-316.1%
Q22026-06-3014.0%
Viva Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.04N/A
20232023-12-31CNY -0.02-50.7%
20242024-12-31CNY 0.01N/A
20252025-12-31CNY 0.0161.7%
Viva Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-67.0%
Q22025-06-30177.8%
Q42025-12-31100.0%
Q22026-06-30-66.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥1.01B

+2.5%

Gross Profit

CN¥341.73M

+0.8%

Gross Margin

33.95%

N/A

Market Cap

$395.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$182.57K

N/A

Employees

2,169

N/A

Net Income

CN¥80.08M

-31.4%

EBITDA

CN¥206.30M

-4.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥1.03B

-1.0%

Total Debt

CN¥898.12M

-41.7%

Accounts Receivable

CN¥250.51M

-43.9%

Inventory

CN¥398.69M

+76.8%

Long Term Debt

CN¥299.56M

-66.3%

Short Term Debt

CN¥598.56M

-8.3%

Return on Assets

2.57%

N/A

Return on Invested Capital

3.33%

N/A

Free Cash Flow

CN¥245.99M

+925.9%

Operating Cash Flow

CN¥346.03M

+127.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTCHFPureTech Health plc
$1.65+0.00%
CLVSFCellaVision AB (publ)
$14.00+0.00%
BOIRFBoiron S.A.
$31.50+0.00%
INRLFValneva SE
$3.29+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$150.54+0.02%
NVDANvidia
$218.40-0.02%
INTCIntel
$101.08-0.05%
BITOProShares Trust - ProShares Bitcoin ETF
$10.40-0.01%

Questions About VBIZF

What is the current price of Viva Biotech?

Viva Biotech is trading at $0.19 per share.

What is the 52-week range for Viva Biotech?

Over the past 52 weeks, Viva Biotech has traded between $0.13 and $0.43.

How much debt does Viva Biotech have?

As of the most recent reporting period, Viva Biotech reported total debt of CN¥190.41M.

How much cash does Viva Biotech have on hand?

Viva Biotech reported CN¥155.80M in cash and cash equivalents in its most recent financial results.

What is Viva Biotech’s dividend yield?

Viva Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services